Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease

Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease

Qian Chen, Hongtao Zhang, Hai-Feng Ji, Zhen Qiao

Since the outbreak of the 2019 novel coronavirus disease (COVID-19), the medical research community is vigorously seeking a treatment to control the infection and save the lives of severely infected patients. The main potential candidates for the control of viruses are virally targeted agents. In this short letter, we report our calculations on the inhibitors for the SARS-CoV-2 3CL protease and the spike protein for the potential treatment of COVID-19. The results show that the most potent inhibitors of the SARS-CoV-2 3CL protease include saquinavir, tadalafil, rivaroxaban, sildenafil, dasatinib, etc. Ergotamine, amphotericin b, and vancomycin are most promising to block the interaction of the SARS-CoV-2 S-protein with human ACE-2.

2020

protease, inhibition, coronavirus, spike protein, computational, COVID-19

DOI: 10.3390/computation8020053

Computation

MDPI AG

Electronic computers. Computer science